Reduced glucose metabolism in specific brain regions (AD “signature”), temporal medial atrophy and regional cortical atrophy consistent with typical or atypical disease phenotypes, decreased Aβ1-42 combined with increased total Tau, and increased p-Tau in CSF all can support the diagnosis; the combination of different abnormalities depends on the spatiotemporal neuropathology trajectory over several years [18,19,20]. Here, MAPT is linked to Alzheimer disease.